Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: According to the Maine Center for Disease Control, the number of syphilis cases reported in the state increased from 48 in 2016 to 84 last year. The number of national syphilis cases increased by 18 percent in between 2015 and 2016. Maine Department of Health and Human Services spokeswoman tells the Bangor Daily News the department isn’t sure why syphilis has increased in recent years. Portland Public Health Center medical director Dr. Christina DeMatteo believes opioid use and waning concerns about HIV have contributed to attitudes about having unprotected sex. Public health advocates say budget cuts resulting in changes in prevention and treatment have also affected rates in the state. ___ Information from: Bangor Daily News, http://www.bangordailynews.com Claim: Maine sees increase in reported syphilis cases.
Example Output: Public health officials in Maine say there has been an increase in syphilis cases, mirroring a national trend.

Example Input: Paragraph: The lawsuit marks the first multi-plaintiff trial in the litigation over whether glyphosate, Roundup’s active ingredient, is carcinogenic, and is the first trial outside of California. It is being held in St. Louis, where Monsanto was headquartered before Bayer bought the company in a $63 billion deal in 2018. Three consecutive juries found the company liable for causing cancer with damages of tens of millions of dollars awarded to each plaintiff. Bayer is appealing those verdicts. Court-appointed mediator Ken Feinberg has put the number of Roundup cancer claimants at more than 75,000 while Bayer said the claims it has been served with in court were below 50,000. Bayer’s share price has tumbled since the first verdict in August 2018 but the stock rose 3% on Friday after Bloomberg reported a possible out-of-court settlement with some plaintiffs that could lead to a total payout of about $10 billion. While traders said the market likes the idea of Bayer settling the litigation, some cautioned that the prospect of a comprehensive deal remained uncertain. Analysts have estimated the size of any such settlement at $8-$12 billion. While most plaintiffs’ lawyers have agreed to postpone trials pending negotiations, some have decided to pursue their clients’ day in court. The case in Missouri’s Circuit Court for the 22nd Judicial Circuit of the City of St. Louis is scheduled to last several weeks, with both sides presenting extensive scientific evidence through expert witnesses. Bayer denies all allegations that Roundup or glyphosate causes cancer, saying decades of independent studies have shown the world’s most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product. “At the end of the day, this trial should come down to the weight of the science, and we remain confident in the extensive scientific record and regulatory assessments that support the safety of our glyphosate-based herbicides and that they do not cause cancer,” the company said in a statement. Several court cases have been postponed by both parties in the past to expedite settlement talks. By pursuing the St. Louis trail The Miller Firm LLC, a key player in the litigation, is seeking to increase pressure on Bayer. The case involves the claims of Bryce Batiste from Louisiana, Ann Meeks from Florida, Glen Ashelman from Pennsylvania and Christopher Wade, a St. Louis resident. All four have been diagnosed with non-Hodgkin’s lymphoma, a blood cell cancer that plaintiffs in the litigation allege is caused by Roundup. Some legal experts said Bayer could benefit from a home advantage in the St. Louis trial, where Monsanto has century-old roots. But juries in the city are also known to dole out massive damages awards against large corporations. Claim: Bayer faces fourth U.S. Roundup cancer trial in Monsanto's hometown.
Example Output: Bayer AG is set to face a fourth U.S. jury trial over allegations that its Roundup weed killer causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to begin making their case on Friday.

Example Input: Paragraph: A woman walks along the boardwalk while leaving the U.S. Open tennis tournament in New York September 4, 2007. REUTERS/Lucas Jackson  Mark Bear and colleagues at the Massachusetts Institute of  Technology studied the effects of a chemical that suppresses  appetite by blocking cannabinoid receptors in the brain, the  same brain mechanisms that make people hungry when they smoke  marijuana. “I think that the cautionary note is that these mechanisms  play an important role in ... brain development,” said Bear,  whose study appears in the journal Neuron. Sanofi-Aventis’ weight-loss pill rimonabant, also known as  Zimulti and sold under the brand name Acomplia in Europe, is  the first in this new class of drugs. A U.S. expert panel  rejected it last June because of fears it might trigger  suicidal thoughts. Other drugmakers, including Merck & Co Inc, are working on  similar drugs. Bear’s team at MIT was hoping to gain insight into how the  brain adapts and rewires itself through learned experiences. This so-called plasticity is central to the development of  neurons in the brain of children and young animals. Bear said these cannabinoid receptors are known to regulate  signals between neurons, and his team wanted to see if they  would have an effect on plasticity in these young mice. They were specifically testing learning in the visual  cortex of the mouse, a part of the brain that processes  information gathered from what they see. Their experiments tested how well the animals adapted if  one eye was closed. The researchers did not use rimonabant in the study. Instead, they used a chemical analog or copy — in this case a  drug available for laboratory use known as AM 251. When they gave the mice AM 251 to block their cannabinoid  receptors, the animals still behaved as if both eyes were open. This suggested the visual cortex was not adapting as it should. “Our finding of a profound disruption of cortical  plasticity in juvenile mice treated with AM 251 suggests  caution is advised in the use of such compounds in children,”  the researchers wrote. Bear said the finding is similar to the situation with many  drugs. “You have to weigh the benefits against the risks. If the  benefit is related more to vanity than morbidity, I don’t think  the risks are tolerable,” he said. Sanofi-Aventis spokeswoman Julissa Viana said rimonabant is  not approved for use in children. “At this point in time it is approved for use in adults who  are overweight and obese with cardiovascular risk factors,” she  said. “We don’t encourage its use in children and it has not  been studied nor is it indicated for use in children.”   A woman walks along the boardwalk while leaving the U.S. Open tennis tournament in New York September 4, 2007. REUTERS/Lucas Jackson  The finding is the latest blow for rimonabant, which once  was predicted to be a multibillion-dollar seller. A study last month of the drug in obese heart patients  found more than 40 percent of patients who took the drug  developed psychiatric problems. But last month the drugmaker Sanofi said it still believes  Acomplia can be a winner and reiterated plans to submit the  drug worldwide as a treatment for type 2 diabetes in 2009. Claim: Weight-loss drugs may harm developing brain: study.
Example Output:
A drug from a new class of weight-loss  treatments disrupted wiring needed for brain development in  young mice, U.S. researchers said on Wednesday, raising  concerns about using such medications in children.